{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T04:47:07Z","timestamp":1771562827371,"version":"3.50.1"},"reference-count":153,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.ejmech.2024.116168","type":"journal-article","created":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T16:39:21Z","timestamp":1706805561000},"page":"116168","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Potential of the nanoplatform and PROTAC interface to achieve targeted protein degradation through the Ubiquitin\u2013Proteasome system"],"prefix":"10.1016","volume":"267","author":[{"given":"Hanshu","family":"Xie","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"21","key":"10.1016\/j.ejmech.2024.116168_bib1","doi-asserted-by":"crossref","DOI":"10.1002\/anie.202200303","article-title":"Chemical biology tools for protein lysine acylation","volume":"61","author":"Xie","year":"2022","journal-title":"Angewandte Chemie-International Edition"},{"issue":"3","key":"10.1016\/j.ejmech.2024.116168_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2022.188734","article-title":"An insight into the ubiquitin-proteasomal axis and related therapeutic approaches towards central nervous system malignancies","volume":"1877","author":"Roy","year":"2022","journal-title":"Biochimica Et Biophysica Acta-Reviews on Cancer"},{"issue":"11","key":"10.1016\/j.ejmech.2024.116168_bib3","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.tibs.2017.09.002","article-title":"The ubiquitin code in the ubiquitin-proteasome system and autophagy","volume":"42","author":"Kwon","year":"2017","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.ejmech.2024.116168_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.105248","article-title":"The ubiquitin-proteasome system and its crosstalk with mitochondria as therapeutic targets in medicine","volume":"163","author":"Kodron","year":"2021","journal-title":"Pharmacol. Res."},{"issue":"8","key":"10.1016\/j.ejmech.2024.116168_bib5","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.tcb.2022.02.005","article-title":"Quality control of protein complex assembly the ubiquitih-proteasome system","volume":"32","author":"Pla-Prats","year":"2022","journal-title":"Trends Cell Biol."},{"key":"10.1016\/j.ejmech.2024.116168_bib6","first-page":"11","volume":"vol. 5","author":"Deng","year":"2020"},{"issue":"8","key":"10.1016\/j.ejmech.2024.116168_bib7","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.molmed.2023.05.006","article-title":"The ubiquitin-proteasome system in breast cancer","volume":"29","author":"Han","year":"2023","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.ejmech.2024.116168_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106627","article-title":"Advancing targeted protein degradation for metabolic diseases therapy","volume":"188","author":"Zhou","year":"2023","journal-title":"Pharmacol. Res."},{"issue":"1","key":"10.1016\/j.ejmech.2024.116168_bib9","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/s41392-022-00966-4","article-title":"Targeted protein degradation: mechanisms, strategies and application","volume":"7","author":"Zhao","year":"2022","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.ejmech.2024.116168_bib10","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.cbpa.2019.11.012","article-title":"Targeted protein degradation: current and future challenges","volume":"56","author":"Hanzl","year":"2020","journal-title":"Curr. Opin. Chem. Biol."},{"issue":"7","key":"10.1016\/j.ejmech.2024.116168_bib11","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.tips.2020.04.005","article-title":"Emerging new concepts of degrader technologies","volume":"41","author":"Ding","year":"2020","journal-title":"Trends Pharmacol. Sci."},{"issue":"8","key":"10.1016\/j.ejmech.2024.116168_bib12","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.chembiol.2020.07.020","article-title":"PROTACs: an emerging therapeutic modality in precision medicine","volume":"27","author":"Nalawansha","year":"2020","journal-title":"Cell Chem. Biol."},{"issue":"14","key":"10.1016\/j.ejmech.2024.116168_bib13","doi-asserted-by":"crossref","first-page":"5740","DOI":"10.1039\/D2CS00200K","article-title":"Target and tissue selectivity of PROTAC degraders","volume":"51","author":"Guenette","year":"2022","journal-title":"Chem. Soc. Rev."},{"issue":"2","key":"10.1016\/j.ejmech.2024.116168_bib14","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.apsb.2019.08.001","article-title":"Degradation of proteins by PROTACs and other strategies","volume":"10","author":"Wang","year":"2020","journal-title":"Acta Pharm. Sin. B"},{"issue":"7","key":"10.1016\/j.ejmech.2024.116168_bib15","doi-asserted-by":"crossref","first-page":"3493","DOI":"10.1021\/acs.jmedchem.0c01689","article-title":"Targeting lysosomal degradation pathways: new strategies and techniques for drug discovery","volume":"64","author":"Pei","year":"2021","journal-title":"J. Med. Chem."},{"issue":"8","key":"10.1016\/j.ejmech.2024.116168_bib16","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1111\/bph.15014","article-title":"Proteolysis-targeting chimeras in drug development: a safety perspective","volume":"177","author":"Moreau","year":"2020","journal-title":"Br. J. Pharmacol."},{"issue":"4","key":"10.1016\/j.ejmech.2024.116168_bib17","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41571-023-00736-3","article-title":"Protein degraders enter the clinic - a new approach to cancer therapy","volume":"20","author":"Chirnomas","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"18","key":"10.1016\/j.ejmech.2024.116168_bib18","doi-asserted-by":"crossref","first-page":"7971","DOI":"10.1039\/D2CS00478J","article-title":"PROTAC degraders as chemical probes for studying target biology and target validation","volume":"51","author":"Nemec","year":"2022","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.ejmech.2024.116168_bib19","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.semcancer.2020.02.006","article-title":"PROTACs: a novel strategy for cancer therapy","volume":"67","author":"Liu","year":"2020","journal-title":"Semin. Cancer Biol."},{"issue":"10","key":"10.1016\/j.ejmech.2024.116168_bib20","first-page":"638","article-title":"Proteomic approaches advancing targeted protein degradation","volume":"21","author":"Sathe","year":"2023","journal-title":"Trends in pharmacological sciences"},{"issue":"257","key":"10.1016\/j.ejmech.2024.116168_bib21","article-title":"Proteolysis-targeting chimeras in biotherapeutics: current trends and future applications","volume":"5","author":"Li","year":"2023","journal-title":"Eur. J. Med. Chem."},{"issue":"13","key":"10.1016\/j.ejmech.2024.116168_bib22","doi-asserted-by":"crossref","first-page":"5330","DOI":"10.1039\/D1CS00762A","article-title":"Proteolysis-targeting chimera (PROTAC) delivery system: advancing protein degraders towards clinical translation","volume":"51","author":"Chen","year":"2022","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.ejmech.2024.116168_bib23","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.cbpa.2020.12.003","article-title":"The rise of covalent proteolysis targeting chimeras","volume":"62","author":"Gabizon","year":"2021","journal-title":"Curr. Opin. Chem. Biol."},{"issue":"2","key":"10.1016\/j.ejmech.2024.116168_bib24","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41573-020-0090-8","article-title":"Engineering precision nanoparticles for drug delivery","volume":"20","author":"Mitchell","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"issue":"4","key":"10.1016\/j.ejmech.2024.116168_bib25","first-page":"924","article-title":"Studies of nanoparticle delivery with in vitro bio-engineered microtissues","volume":"5","author":"Sun","year":"2020","journal-title":"Bioact. Mater."},{"issue":"327","key":"10.1016\/j.ejmech.2024.116168_bib26","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.jconrel.2020.08.012","article-title":"Controlled anti-cancer drug release through advanced nano-drug delivery systems: static and dynamic targeting strategies","volume":"10","author":"Kashkooli","year":"2020","journal-title":"J. Contr. Release"},{"issue":"10","key":"10.1016\/j.ejmech.2024.116168_bib27","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1038\/s41565-020-0759-5","article-title":"A framework for designing delivery systems","volume":"15","author":"Poon","year":"2020","journal-title":"Nat. Nanotechnol."},{"issue":"7","key":"10.1016\/j.ejmech.2024.116168_bib28","doi-asserted-by":"crossref","first-page":"7410","DOI":"10.1021\/acsnano.9b03924","article-title":"Role of nanoparticle mechanical properties in cancer drug delivery","volume":"13","author":"Hui","year":"2019","journal-title":"ACS Nano"},{"issue":"6","key":"10.1016\/j.ejmech.2024.116168_bib29","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.molmed.2021.04.002","article-title":"Historical perspective of clinical nano and microparticle formulations for delivery of therapeutics","volume":"27","author":"Batty","year":"2021","journal-title":"Trends Mol. Med."},{"issue":"11","key":"10.1016\/j.ejmech.2024.116168_bib30","doi-asserted-by":"crossref","first-page":"4098","DOI":"10.1016\/j.apsb.2022.08.013","article-title":"Smart drug delivery systems for precise cancer therapy","volume":"12","author":"Wang","year":"2022","journal-title":"Acta Pharm. Sin. B"},{"issue":"7","key":"10.1016\/j.ejmech.2024.116168_bib31","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1038\/s41581-019-0148-1","article-title":"The ubiquitin-proteasome system in kidney physiology and disease","volume":"15","author":"Meyer-Schwesinger","year":"2019","journal-title":"Nat. Rev. Nephrol."},{"key":"10.1016\/j.ejmech.2024.116168_bib32","first-page":"16","volume":"vol. 6","author":"Zhou","year":"2021"},{"issue":"2","key":"10.1016\/j.ejmech.2024.116168_bib33","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1124\/pr.117.015370","article-title":"A practical review of proteasome pharmacology","volume":"71","author":"Thibaudeau","year":"2019","journal-title":"Pharmacol. Rev."},{"issue":"9","key":"10.1016\/j.ejmech.2024.116168_bib34","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1021\/acs.accounts.1c00144","article-title":"Chemical catalysis intervening to histone epigenetics","volume":"54","author":"Nozaki","year":"2021","journal-title":"Accounts of Chemical Research"},{"key":"10.1016\/j.ejmech.2024.116168_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2020.101203","article-title":"The dialogue between the ubiquitin-proteasome system and autophagy: implications in ageing","volume":"64","author":"Sun-Wang","year":"2020","journal-title":"Ageing Res. Rev."},{"issue":"6467","key":"10.1016\/j.ejmech.2024.116168_bib36","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1126\/science.aax3769","article-title":"Cellular quality control by the ubiquitin-proteasome system and autophagy","volume":"366","author":"Pohl","year":"2019","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.ejmech.2024.116168_bib37","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1164\/rccm.201304-0754PP","article-title":"The emerging role of the ubiquitin proteasome in pulmonary biology and disease","volume":"188","author":"Weathington","year":"2013","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.ejmech.2024.116168_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2020.101088","article-title":"The potential roles of deubiquitinating enzymes in brain diseases","volume":"61","author":"Lim","year":"2020","journal-title":"Ageing Res. Rev."},{"issue":"7","key":"10.1016\/j.ejmech.2024.116168_bib39","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.tcb.2010.03.007","article-title":"Assembly, structure, and function of the 26S proteasome","volume":"20","author":"Bedford","year":"2010","journal-title":"Trends Cell Biol."},{"issue":"87","key":"10.1016\/j.ejmech.2024.116168_bib40","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1146\/annurev-biochem-062917-011931","article-title":"Structure and function of the 26S proteasome","volume":"20","author":"Bard","year":"2018","journal-title":"Annu. Rev. Biochem."},{"issue":"11","key":"10.1016\/j.ejmech.2024.116168_bib41","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.tibs.2022.06.006","article-title":"Proteasome substrate receptors and their therapeutic potential","volume":"47","author":"Osei-Amponsa","year":"2022","journal-title":"Trends Biochem. Sci."},{"issue":"6","key":"10.1016\/j.ejmech.2024.116168_bib42","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.tcb.2013.12.003","article-title":"Perilous journey: a tour of the ubiquitin-proteasome system","volume":"24","author":"Kleiger","year":"2014","journal-title":"Trends Cell Biol."},{"issue":"560","key":"10.1016\/j.ejmech.2024.116168_bib43","article-title":"PROTACs: novel tools for improving immunotherapy in cancer","volume":"28","author":"Li","year":"2023","journal-title":"Cancer Lett."},{"issue":"16","key":"10.1016\/j.ejmech.2024.116168_bib44","doi-asserted-by":"crossref","first-page":"7066","DOI":"10.1039\/D2CS00220E","article-title":"Chemistries of bifunctional PROTAC degraders","volume":"51","author":"Cao","year":"2022","journal-title":"Chem. Soc. Rev."},{"issue":"7","key":"10.1016\/j.ejmech.2024.116168_bib45","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1021\/acs.accounts.1c00065","article-title":"Reimagining druggability using chemoproteomic platforms","volume":"54","author":"Spradlin","year":"2021","journal-title":"Accounts of Chemical Research"},{"issue":"255","key":"10.1016\/j.ejmech.2024.116168_bib46","article-title":"Bifunctional robots inducing targeted protein degradation","volume":"5","author":"Sobhia","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116168_bib47","first-page":"64","volume":"vol. 24","author":"Sun","year":"2019"},{"issue":"539","key":"10.1016\/j.ejmech.2024.116168_bib48","article-title":"Proteolysis-targeting chimeras: a promising technique in cancer therapy for gaining insights into tumor development","volume":"28","author":"Lv","year":"2022","journal-title":"Cancer Lett."},{"issue":"1","key":"10.1016\/j.ejmech.2024.116168_bib49","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s13045-020-00885-3","article-title":"Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy","volume":"13","author":"Li","year":"2020","journal-title":"J. Hematol. Oncol."},{"issue":"10","key":"10.1016\/j.ejmech.2024.116168_bib50","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/s41573-021-00245-x","article-title":"The PROTACtable genome","volume":"20","author":"Schneider","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2024.116168_bib51","first-page":"181","volume":"vol. 7","author":"He","year":"2022"},{"issue":"1","key":"10.1016\/j.ejmech.2024.116168_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2022.103417","article-title":"PROTACting the kinome with covalent warheads","volume":"28","author":"Chatterjee","year":"2023","journal-title":"Drug Discov. Today"},{"issue":"10","key":"10.1016\/j.ejmech.2024.116168_bib53","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/s41568-021-00365-x","article-title":"Advancing targeted protein degradation for cancer therapy","volume":"21","author":"Dale","year":"2021","journal-title":"Nat. Rev. Cancer"},{"issue":"3","key":"10.1016\/j.ejmech.2024.116168_bib54","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41573-021-00371-6","article-title":"PROTAC targeted protein degraders: the past is prologue","volume":"21","author":"Bekes","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"issue":"11","key":"10.1016\/j.ejmech.2024.116168_bib55","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/s41568-019-0196-7","article-title":"Targeting transcription factors in cancer - from undruggable to reality","volume":"19","author":"Bushweller","year":"2019","journal-title":"Nat. Rev. Cancer"},{"issue":"1","key":"10.1016\/j.ejmech.2024.116168_bib56","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s13045-020-00924-z","article-title":"Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies","volume":"13","author":"He","year":"2020","journal-title":"J. Hematol. Oncol."},{"issue":"91","key":"10.1016\/j.ejmech.2024.116168_bib57","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1146\/annurev-biochem-032620-104421","article-title":"Driving E3 ligase substrate specificity for targeted protein degradation: lessons from nature and the laboratory","volume":"21","author":"Cowan","year":"2022","journal-title":"Annu. Rev. Biochem."},{"issue":"7","key":"10.1016\/j.ejmech.2024.116168_bib58","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.chembiol.2021.04.007","article-title":"Expanding the arsenal of E3 ubiquitin ligases for proximity-induced protein degradation","volume":"28","author":"Kannt","year":"2021","journal-title":"Cell Chem. Biol."},{"issue":"9","key":"10.1016\/j.ejmech.2024.116168_bib59","doi-asserted-by":"crossref","first-page":"3487","DOI":"10.1039\/D2CS00148A","article-title":"E3 ligase ligand chemistries: from building blocks to protein degraders","volume":"51","author":"Sosic","year":"2022","journal-title":"Chem. Soc. Rev."},{"issue":"262","key":"10.1016\/j.ejmech.2024.116168_bib60","article-title":"Recent progress in degradation of membrane proteins by PROTACs and alternative targeted protein degradation techniques","volume":"15","author":"Chen","year":"2023","journal-title":"Eur. J. Med. Chem."},{"issue":"11","key":"10.1016\/j.ejmech.2024.116168_bib61","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.7150\/ijbs.83026","article-title":"Emerging pharmacotherapeutic strategies to overcome undruggable proteins in cancer","volume":"19","author":"Lu","year":"2023","journal-title":"Int. J. Biol. Sci."},{"issue":"22","key":"10.1016\/j.ejmech.2024.116168_bib62","doi-asserted-by":"crossref","first-page":"10141","DOI":"10.7150\/thno.46985","article-title":"The peptide PROTAC modality: a novel strategy for targeted protein ubiquitination","volume":"10","author":"Jin","year":"2020","journal-title":"Theranostics"},{"issue":"13","key":"10.1016\/j.ejmech.2024.116168_bib63","doi-asserted-by":"crossref","first-page":"8884","DOI":"10.1021\/acs.jmedchem.1c00629","article-title":"Recent update on development of small-molecule STAT3 inhibitors for cancer therapy: from phosphorylation inhibition to protein degradation","volume":"64","author":"Dong","year":"2021","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.ejmech.2024.116168_bib64","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s12943-020-01258-7","article-title":"Targeting STAT3 in cancer immunotherapy","volume":"19","author":"Zou","year":"2020","journal-title":"Mol. Cancer"},{"issue":"5","key":"10.1016\/j.ejmech.2024.116168_bib65","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.ccell.2019.10.002","article-title":"A potent and selective small-molecule degrader of STAT3 achieves complete tumor regression <i>In vivo<\/i&gt","volume":"36","author":"Bai","year":"2019","journal-title":"Cancer Cell"},{"issue":"6","key":"10.1016\/j.ejmech.2024.116168_bib66","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/s41589-022-01248-4","article-title":"A selective small-molecule STAT5 PROTAC degrader capable of achieving tumor regression in vivo","volume":"19","author":"Kaneshige","year":"2023","journal-title":"Nat. Chem. Biol."},{"issue":"2","key":"10.1016\/j.ejmech.2024.116168_bib67","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/leu.2017.207","article-title":"BET protein proteolysis targeting chimera (PROTAC) exerts potent lethal activity against mantle cell lymphoma cells","volume":"32","author":"Sun","year":"2018","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.ejmech.2024.116168_bib68","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1186\/s13046-019-1387-5","article-title":"Activity of BET-proteolysis targeting chimeric (PROTAC) compounds in triple negative breast cancer","volume":"38","author":"del Mar Noblejas-Lopez","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2024.116168_bib69","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106529","article-title":"Selective PARP1 inhibitors, PARP1-based dual-target inhibitors, PROTAC PARP1 degraders, and prodrugs of PARP1 inhibitors for cancer therapy","volume":"186","author":"Peng","year":"2022","journal-title":"Pharmacol. Res."},{"issue":"19","key":"10.1016\/j.ejmech.2024.116168_bib70","doi-asserted-by":"crossref","first-page":"11012","DOI":"10.1021\/acs.jmedchem.0c00821","article-title":"Discovery of SK-575 as a highly potent and efficacious proteolysis-targeting chimera degrader of PARP1 for treating cancers","volume":"63","author":"Cao","year":"2020","journal-title":"J. Med. Chem."},{"issue":"11","key":"10.1016\/j.ejmech.2024.116168_bib71","doi-asserted-by":"crossref","first-page":"7839","DOI":"10.1021\/acs.jmedchem.1c00649","article-title":"Rational design and synthesis of novel dual PROTACs for simultaneous degradation of EGFR and PARP","volume":"64","author":"Zheng","year":"2021","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.ejmech.2024.116168_bib72","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.cell.2012.03.003","article-title":"MYC on the path to cancer","volume":"149","author":"Dang","year":"2012","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.ejmech.2024.116168_bib73","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S0092-8674(02)01284-9","article-title":"X-ray structures of Myc-Max and Mad-Max recognizing DNA. Molecular bases of regulation by proto-oncogenic transcription factors","volume":"112","author":"Nair","year":"2003","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2024.116168_bib74","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.semcancer.2020.11.008","article-title":"Epigenetic modifications of c-MYC: role in cancer cell reprogramming, progression and chemoresistance","volume":"83","author":"Fatma","year":"2022","journal-title":"Semin. Cancer Biol."},{"issue":"3","key":"10.1016\/j.ejmech.2024.116168_bib75","doi-asserted-by":"crossref","first-page":"53","DOI":"10.3390\/biom7030053","article-title":"MYC-driven pathways in breast cancer subtypes","volume":"7","author":"Fallah","year":"2017","journal-title":"Biomolecules"},{"key":"10.1016\/j.ejmech.2024.116168_bib76","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2021.103756","article-title":"Therapeutic targeting of \"undruggable\" MYC","volume":"75","author":"Llombart","year":"2022","journal-title":"EBioMedicine"},{"issue":"16","key":"10.1016\/j.ejmech.2024.116168_bib77","doi-asserted-by":"crossref","first-page":"9334","DOI":"10.1021\/jacs.3c02619","article-title":"c-Myc-Targeting PROTAC based on a TNA-DNA bivalent binder for combination therapy of triple-negative breast cancer","volume":"145","author":"Li","year":"2023","journal-title":"J. Am. Chem. Soc."},{"issue":"1","key":"10.1016\/j.ejmech.2024.116168_bib78","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1186\/s13046-022-02483-2","article-title":"Peptide-based PROTAC degrader of FOXM1 suppresses cancer and decreases GLUT1 and PD-L1 expression","volume":"41","author":"Wang","year":"2022","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"49","key":"10.1016\/j.ejmech.2024.116168_bib79","article-title":"A short binding site in the KPC1 ubiquitin ligase mediates processing of NF-kappa B1 p105 to p50: a potential for a tumor-suppressive PROTAC","volume":"118","author":"Goldhirsh","year":"2021","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.ejmech.2024.116168_bib80","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.semcancer.2023.03.007","article-title":"FOXM1: a small fox that makes more tracks for cancer progression and metastasis","volume":"92","author":"Khan","year":"2023","journal-title":"Semin. Cancer Biol."},{"issue":"11","key":"10.1016\/j.ejmech.2024.116168_bib81","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1158\/0008-5472.CAN-21-3371","article-title":"Forkhead box transcription factors: double-edged swords in cancer","volume":"82","author":"Castaneda","year":"2022","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.ejmech.2024.116168_bib82","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/s41392-020-00312-6","article-title":"Targeting NF-kappa B pathway for the therapy of diseases: mechanism and clinical study","volume":"5","author":"Yu","year":"2020","journal-title":"Signal Transduct. Targeted Ther."},{"issue":"8","key":"10.1016\/j.ejmech.2024.116168_bib83","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.trecan.2020.04.003","article-title":"NF-Kappa B in the new era of cancer therapy","volume":"6","author":"Eluard","year":"2020","journal-title":"Trends in Cancer"},{"issue":"4","key":"10.1016\/j.ejmech.2024.116168_bib84","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.cell.2022.12.032","article-title":"Hallmarks of neurodegenerative diseases","volume":"186","author":"Wilson","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2024.116168_bib85","article-title":"Targeted protein degraders march towards the clinic for neurodegenerative diseases","volume":"78","author":"Hassan","year":"2022","journal-title":"Ageing Res. Rev."},{"issue":"7","key":"10.1016\/j.ejmech.2024.116168_bib86","doi-asserted-by":"crossref","first-page":"3346","DOI":"10.1002\/anie.202004746","article-title":"PROTACs and other chemical protein degradation technologies for the treatment of neurodegenerative disorders","volume":"60","author":"Tomoshige","year":"2021","journal-title":"Angewandte Chemie-International Edition"},{"issue":"11","key":"10.1016\/j.ejmech.2024.116168_bib87","doi-asserted-by":"crossref","first-page":"5279","DOI":"10.7150\/thno.55680","article-title":"A novel small-molecule PROTAC selectively promotes tau clearance to improve cognitive functions in Alzheimer-like models","volume":"11","author":"Wang","year":"2021","journal-title":"Theranostics"},{"key":"10.1016\/j.ejmech.2024.116168_bib88","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.45457","article-title":"Targeted degradation of aberrant tau in frontotemporal dementia patient-derived neuronal cell models","volume":"8","author":"Silva","year":"2019","journal-title":"Elife"},{"issue":"5","key":"10.1016\/j.ejmech.2024.116168_bib89","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1212\/WNL.0000000000200878","article-title":"Alpha-synuclein seed amplification assays for diagnosing synucleinopathies the way forward","volume":"99","author":"Bellomo","year":"2022","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.ejmech.2024.116168_bib90","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1007\/s00401-019-02010-2","article-title":"Selective vulnerability in alpha-synucleinopathies","volume":"138","author":"Alegre-Abarrategui","year":"2019","journal-title":"Acta Neuropathol."},{"issue":"1","key":"10.1016\/j.ejmech.2024.116168_bib91","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s13024-019-0320-x","article-title":"alpha-synuclein in the pathophysiology of Alzheimer's disease","volume":"14","author":"Twohig","year":"2019","journal-title":"Mol. Neurodegener."},{"issue":"12","key":"10.1016\/j.ejmech.2024.116168_bib92","doi-asserted-by":"crossref","first-page":"7926","DOI":"10.1021\/acs.jmedchem.3c00274","article-title":"Discovery of small-molecule degraders for alpha-synuclein aggregates","volume":"66","author":"Tong","year":"2023","journal-title":"J. Med. Chem."},{"issue":"10360","key":"10.1016\/j.ejmech.2024.116168_bib93","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1016\/S0140-6736(22)01272-7","article-title":"Amyotrophic lateral sclerosis","volume":"400","author":"Feldman","year":"2022","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.ejmech.2024.116168_bib94","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/S1474-4422(21)00414-2","article-title":"Emerging insights into the complex genetics and pathophysiology of amyotrophic lateral sclerosis","volume":"21","author":"Goutman","year":"2022","journal-title":"Lancet Neurol."},{"issue":"1","key":"10.1016\/j.ejmech.2024.116168_bib95","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s12929-023-00921-7","article-title":"Degradation of neurodegenerative disease-associated TDP-43 aggregates and oligomers via a proteolysis-targeting chimera","volume":"30","author":"Tseng","year":"2023","journal-title":"J. Biomed. Sci."},{"issue":"18","key":"10.1016\/j.ejmech.2024.116168_bib96","doi-asserted-by":"crossref","first-page":"3708","DOI":"10.1016\/j.molcel.2021.08.027","article-title":"Lipid metabolism in sickness and in health: emerging regulators of lipotoxicity","volume":"81","author":"Yoon","year":"2021","journal-title":"Mol. Cell"},{"issue":"5","key":"10.1016\/j.ejmech.2024.116168_bib97","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/j.apsb.2020.11.001","article-title":"Discovery of an orally active VHL-recruiting PROTAC that achieves robust HMGCR degradation and potent hypolipidemic activity in vivo","volume":"11","author":"Luo","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"issue":"19","key":"10.1016\/j.ejmech.2024.116168_bib98","doi-asserted-by":"crossref","first-page":"9521","DOI":"10.1073\/pnas.1901974116","article-title":"Accumulation of PNPLA3 on lipid droplets is the basis of associated hepatic steatosis","volume":"116","author":"BasuRay","year":"2019","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"9","key":"10.1016\/j.ejmech.2024.116168_bib99","article-title":"Development of agonist-based PROTACs targeting liver X receptor","volume":"26","author":"Xu","year":"2021","journal-title":"Front. Chem."},{"issue":"11","key":"10.1016\/j.ejmech.2024.116168_bib100","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.tips.2023.05.008","article-title":"Leveraging aptamers for targeted protein degradation","volume":"44","author":"Yang","year":"2023","journal-title":"Trends in pharmacological sciences"},{"issue":"1","key":"10.1016\/j.ejmech.2024.116168_bib101","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.cell.2019.11.031","article-title":"Proteolysis-targeting chimeras as therapeutics and tools for biological discovery","volume":"181","author":"Burslem","year":"2020","journal-title":"Cell"},{"issue":"20","key":"10.1016\/j.ejmech.2024.116168_bib102","doi-asserted-by":"crossref","first-page":"11615","DOI":"10.1021\/acs.jmedchem.0c00793","article-title":"Understanding the metabolism of proteolysis targeting chimeras (PROTACs): the next step toward pharmaceutical applications","volume":"63","author":"Goracci","year":"2020","journal-title":"J. Med. Chem."},{"issue":"8","key":"10.1016\/j.ejmech.2024.116168_bib103","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1016\/j.apsb.2020.11.023","article-title":"Evolution of blood-brain barrier in brain diseases and related systemic nanoscale brain-targeting drug delivery strategies","volume":"11","author":"Han","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"issue":"4","key":"10.1016\/j.ejmech.2024.116168_bib104","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/nrd.2015.21","article-title":"From blood-brain barrier to blood-brain interface: new opportunities for CNS drug delivery","volume":"15","author":"Banks","year":"2016","journal-title":"Nat. Rev. Drug Discov."},{"issue":"331","key":"10.1016\/j.ejmech.2024.116168_bib105","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.jconrel.2020.08.045","article-title":"Nanoscale drug delivery systems for controllable drug behaviors by multi-stage barrier penetration","volume":"10","author":"Wang","year":"2021","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.ejmech.2024.116168_bib106","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2021.120737","article-title":"Smart transformable nanomedicines for cancer therapy","volume":"271","author":"Wang","year":"2021","journal-title":"Biomaterials"},{"key":"10.1016\/j.ejmech.2024.116168_bib107","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2021.113994","article-title":"Delivering more for less: nanosized, minimal-carrier and pharmacoactive drug delivery systems","volume":"179","author":"Etter","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"10","key":"10.1016\/j.ejmech.2024.116168_bib108","article-title":"Polymeric nanoparticles-Promising carriers for cancer therapy","volume":"7","author":"Xiao","year":"2022","journal-title":"Front. Bioeng. Biotechnol."},{"issue":"4","key":"10.1016\/j.ejmech.2024.116168_bib109","doi-asserted-by":"crossref","first-page":"298","DOI":"10.3390\/pharmaceutics12040298","article-title":"Polymeric nanocarriers of drug delivery systems in cancer therapy","volume":"12","author":"Avramovic","year":"2020","journal-title":"Pharmaceutics"},{"issue":"4","key":"10.1016\/j.ejmech.2024.116168_bib110","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/s41573-018-0005-0","article-title":"Polymer-drug conjugate therapeutics: advances, insights and prospects","volume":"18","author":"Ekladious","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"issue":"286","key":"10.1016\/j.ejmech.2024.116168_bib111","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.jconrel.2018.07.041","article-title":"Single-chain polymer nanoparticles in controlled drug delivery and targeted imaging","volume":"28","author":"Kroger","year":"2018","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.ejmech.2024.116168_bib112","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.addr.2020.07.020","article-title":"Polymer nanomedicines","volume":"156","author":"Kopecek","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejmech.2024.116168_bib113","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.jconrel.2022.09.031","article-title":"Polyethylene glycol (PEG): the nature, immunogenicity, and role in the hypersensitivity of PEGylated products","volume":"351","author":"Ibrahim","year":"2022","journal-title":"J. Contr. Release"},{"issue":"11","key":"10.1016\/j.ejmech.2024.116168_bib114","doi-asserted-by":"crossref","first-page":"16982","DOI":"10.1021\/acsnano.1c04996","article-title":"Lipid nanoparticles-from liposomes to mRNA vaccine delivery, a landscape of research diversity and advancement","volume":"15","author":"Tenchov","year":"2021","journal-title":"ACS Nano"},{"issue":"2","key":"10.1016\/j.ejmech.2024.116168_bib115","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1039\/D0NH00605J","article-title":"Targeted liposomal drug delivery: a nanoscience and biophysical perspective","volume":"6","author":"Liu","year":"2021","journal-title":"Nanoscale Horizons"},{"issue":"17","key":"10.1016\/j.ejmech.2024.116168_bib116","doi-asserted-by":"crossref","first-page":"7509","DOI":"10.7150\/thno.77259","article-title":"Lipid nanoparticles for delivery of RNA therapeutics Current status and the role of in vivo imaging","volume":"12","author":"Jung","year":"2022","journal-title":"Theranostics"},{"key":"10.1016\/j.ejmech.2024.116168_bib117","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2021.114097","article-title":"Oral delivery of therapeutic peptides and proteins: technology landscape of lipid-based nanocarriers","volume":"182","author":"Haddadzadegan","year":"2022","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejmech.2024.116168_bib118","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2023.114770","article-title":"Polymer- and lipid-based nanocarriers for ocular drug delivery: current status and future perspectives","volume":"196","author":"Han","year":"2023","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"1","key":"10.1016\/j.ejmech.2024.116168_bib119","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41596-022-00755-x","article-title":"Preparation of selective organ-targeting (SORT) lipid nanoparticles (LNPs) using multiple technical methods for tissue-specific mRNA delivery","volume":"18","author":"Wang","year":"2023","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.ejmech.2024.116168_bib120","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.addr.2020.06.020","article-title":"Delivery of drugs, proteins, and nucleic acids using inorganic nanoparticles","volume":"156","author":"Luther","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"2","key":"10.1016\/j.ejmech.2024.116168_bib121","doi-asserted-by":"crossref","first-page":"411","DOI":"10.3390\/pharmaceutics15020411","article-title":"Cancer-specific delivery of proteolysis-targeting chimeras (PROTACs) and their application to cancer immunotherapy","volume":"15","author":"Moon","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejmech.2024.116168_bib122","doi-asserted-by":"crossref","DOI":"10.1016\/j.colsurfb.2020.110795","article-title":"Targeted degradation of anaplastic lymphoma kinase by gold nanoparticle-based multi-headed proteolysis targeting chimeras","volume":"188","author":"Wang","year":"2020","journal-title":"Colloids and Surfaces B-Biointerfaces"},{"key":"10.1016\/j.ejmech.2024.116168_bib123","doi-asserted-by":"crossref","DOI":"10.1016\/j.biotechadv.2022.108032","article-title":"Protein scaffolds in human clinics","volume":"61","author":"Cano-Garrido","year":"2022","journal-title":"Biotechnol. Adv."},{"issue":"1","key":"10.1016\/j.ejmech.2024.116168_bib124","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/s12951-021-00896-3","article-title":"Protein nanoparticles in drug delivery: animal protein, plant proteins and protein cages, albumin nanoparticles","volume":"19","author":"Kianfar","year":"2021","journal-title":"J. Nanobiotechnol."},{"issue":"2","key":"10.1016\/j.ejmech.2024.116168_bib125","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3109\/07388551.2013.833163","article-title":"Engineering protein self-assembling in protein-based nanomedicines for drug delivery and gene therapy","volume":"35","author":"Ferrer-Miralles","year":"2015","journal-title":"Crit. Rev. Biotechnol."},{"issue":"7","key":"10.1016\/j.ejmech.2024.116168_bib126","doi-asserted-by":"crossref","first-page":"604","DOI":"10.3390\/pharmaceutics12070604","article-title":"Protein-based nanoparticles as drug delivery systems","volume":"12","author":"Hong","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejmech.2024.116168_bib127","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2023.122038","article-title":"In situ albumin-binding and esterase-specifically cleaved BRD4-degrading PROTAC for targeted cancer therapy","volume":"295","author":"Cho","year":"2023","journal-title":"Biomaterials"},{"issue":"6","key":"10.1016\/j.ejmech.2024.116168_bib128","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1016\/j.apsb.2022.02.009","article-title":"A BRD4 PROTAC nanodrug for glioma therapy via the intervention of tumor cells proliferation, apoptosis and M2 macrophages polarization","volume":"12","author":"Yang","year":"2022","journal-title":"Acta Pharm. Sin. B"},{"issue":"29","key":"10.1016\/j.ejmech.2024.116168_bib129","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202202039","article-title":"Versatile nano-PROTAC-induced epigenetic reader degradation for efficient lung cancer therapy","volume":"9","author":"Zhang","year":"2022","journal-title":"Adv. Sci."},{"issue":"330","key":"10.1016\/j.ejmech.2024.116168_bib130","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1016\/j.jconrel.2020.11.032","article-title":"Enhanced protein degradation by intracellular delivery of pre-fused PROTACs using lipid-like nanoparticles","volume":"10","author":"Chen","year":"2021","journal-title":"J. Contr. Release"},{"issue":"16","key":"10.1016\/j.ejmech.2024.116168_bib131","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202207439","article-title":"Glutathione-scavenging nanoparticle-mediated PROTACs delivery for targeted protein degradation and amplified antitumor effects","volume":"10","author":"Liu","year":"2023","journal-title":"Adv. Sci."},{"key":"10.1016\/j.ejmech.2024.116168_bib132","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.jconrel.2014.12.030","article-title":"Nanomedicine in cancer therapy: challenges, opportunities, and clinical applications","volume":"200","author":"Wicki","year":"2015","journal-title":"J. Contr. Release"},{"issue":"10","key":"10.1016\/j.ejmech.2024.116168_bib133","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.tips.2020.08.008","article-title":"Nanoformulation of BRD4-degrading PROTAC: improving druggability to target the 'undruggable' MYC in pancreatic cancer","volume":"41","author":"Minko","year":"2020","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.ejmech.2024.116168_bib134","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jconrel.2022.12.035","article-title":"Brd4 proteolysis-targeting chimera nanoparticles sensitized colorectal cancer chemotherapy","volume":"354","author":"He","year":"2023","journal-title":"J. Contr. Release"},{"issue":"10","key":"10.1016\/j.ejmech.2024.116168_bib135","doi-asserted-by":"crossref","first-page":"986","DOI":"10.3390\/pharmaceutics12100986","article-title":"Controlled delivery of BET-PROTACs: in vitro evaluation of MZ1-loaded polymeric antibody conjugated nanoparticles in breast cancer","volume":"12","author":"Cimas","year":"2020","journal-title":"Pharmaceutics"},{"issue":"12","key":"10.1016\/j.ejmech.2024.116168_bib136","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202210787","article-title":"A physiologically responsive nanocomposite hydrogel for treatment of head and neck squamous cell carcinoma via proteolysis-targeting chimeras enhanced immunotherapy","volume":"35","author":"Wu","year":"2023","journal-title":"Adv. Mater."},{"issue":"1","key":"10.1016\/j.ejmech.2024.116168_bib137","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/s41571-022-00699-x","article-title":"Targeting drugs to tumours using cell membrane-coated nanoparticles","volume":"20","author":"Fang","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.ejmech.2024.116168_bib138","doi-asserted-by":"crossref","first-page":"2934","DOI":"10.1038\/s41467-021-23194-w","article-title":"Semiconducting polymer nano-PROTACs for activatable photo-immunometabolic cancer therapy","volume":"12","author":"Zhang","year":"2021","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.ejmech.2024.116168_bib139","doi-asserted-by":"crossref","first-page":"4318","DOI":"10.1038\/s41467-022-32050-4","article-title":"Engineered bioorthogonal POLY-PROTAC nanoparticles for tumour-specific protein degradation and precise cancer therapy","volume":"13","author":"Gao","year":"2022","journal-title":"Nat. Commun."},{"issue":"7","key":"10.1016\/j.ejmech.2024.116168_bib140","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.3390\/pharmaceutics13071005","article-title":"Development of dual ARV-825 and nintedanib-loaded PEGylated nano-liposomes for synergistic efficacy in vemurafnib-resistant melanoma","volume":"13","author":"Fu","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejmech.2024.116168_bib141","article-title":"PROTAC nanoplatform with targeted degradation of NAD(P)H:quinone oxidoreductase 1 to enhance reactive oxygen species-mediated apoptosis","author":"Zhang","year":"2023","journal-title":"Acs Applied Materials & Interfaces"},{"issue":"9","key":"10.1016\/j.ejmech.2024.116168_bib142","doi-asserted-by":"crossref","first-page":"6263","DOI":"10.1021\/acs.jmedchem.3c00013","article-title":"Persistent degradation of HER2 protein by hybrid nanoPROTAC for programmed cell death","volume":"66","author":"Wang","year":"2023","journal-title":"J. Med. Chem."},{"issue":"20","key":"10.1016\/j.ejmech.2024.116168_bib147","first-page":"404","article-title":"Carrier-free nanoprodrug for p53-mutated tumor therapy via concurrent delivery of zinc-manganese dual ions and ROS","volume":"18","author":"Wang","year":"2023","journal-title":"Bioact. Mater."},{"key":"10.1016\/j.ejmech.2024.116168_bib148","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2021.120720","article-title":"Glutathionylation-dependent proteasomal degradation of wide-spectrum mutant p53 proteins by engineered zeolitic imidazolate framework-8","volume":"271","author":"Zhang","year":"2021","journal-title":"Biomaterials"},{"issue":"1","key":"10.1016\/j.ejmech.2024.116168_bib150","article-title":"Precise pancreatic cancer therapy through targeted degradation of mutant p53 protein by cerium oxide nanoparticles","volume":"21","author":"Zhang","year":"2023","journal-title":"J. Nanobiotechnol."},{"issue":"1","key":"10.1016\/j.ejmech.2024.116168_bib151","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1186\/s13578-020-00508-x","article-title":"Arsenic nano complex induced degradation of YAP sensitized ESCC cancer cells to radiation and chemotherapy","volume":"10","author":"Zhou","year":"2020","journal-title":"Cell Biosci."},{"key":"10.1016\/j.ejmech.2024.116168_bib152","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2021.121287","article-title":"Inhibiting autophagy flux and DNA repair of tumor cells to boost radiotherapy of orthotopic glioblastoma","volume":"280","author":"Xu","year":"2022","journal-title":"Biomaterials"},{"key":"10.1016\/j.ejmech.2024.116168_bib153","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2019.119248","article-title":"MnFe2O4 nanoparticles accelerate the clearance of mutant huntingtin selectively through ubiquitin-proteasome system","volume":"216","author":"Zhang","year":"2019","journal-title":"Biomaterials"},{"issue":"2","key":"10.1016\/j.ejmech.2024.116168_bib143","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/s41573-022-00571-8","article-title":"Drugging p53 in cancer: one protein, many targets","volume":"22","author":"Hassin","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"issue":"1","key":"10.1016\/j.ejmech.2024.116168_bib144","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1186\/s13045-021-01169-0","article-title":"Targeting mutant p53 for cancer therapy: direct and indirect strategies","volume":"14","author":"Hu","year":"2021","journal-title":"J. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.ejmech.2024.116168_bib145","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1021\/acsami.2c18020","article-title":"Crizotinib nanomicelles synergize with chemotherapy through inducing proteasomal degradation of Mutp53 proteins","volume":"15","author":"Yi","year":"2023","journal-title":"Acs Applied Materials & Interfaces"},{"key":"10.1016\/j.ejmech.2024.116168_bib146","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.semcancer.2020.07.005","article-title":"Targeting p53 for the treatment of cancer","volume":"79","author":"Duffy","year":"2022","journal-title":"Semin. Cancer Biol."},{"issue":"150","key":"10.1016\/j.ejmech.2024.116168_bib149","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.actbio.2022.07.057","article-title":"Length Proteasomal and autophagy-mediated degradation of mutp53 proteins through mitochondria-targeting aggregation-induced-emission materials","volume":"15","author":"Wang","year":"2022","journal-title":"Acta Biomater."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523424000485?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523424000485?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,24]],"date-time":"2024-12-24T19:18:01Z","timestamp":1735067881000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523424000485"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":153,"alternative-id":["S0223523424000485"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2024.116168","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Potential of the nanoplatform and PROTAC interface to achieve targeted protein degradation through the Ubiquitin\u2013Proteasome system","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2024.116168","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"116168"}}